RU2404795C2 - Способы лечения почечно-клеточной карциномы - Google Patents

Способы лечения почечно-клеточной карциномы Download PDF

Info

Publication number
RU2404795C2
RU2404795C2 RU2007132125/14A RU2007132125A RU2404795C2 RU 2404795 C2 RU2404795 C2 RU 2404795C2 RU 2007132125/14 A RU2007132125/14 A RU 2007132125/14A RU 2007132125 A RU2007132125 A RU 2007132125A RU 2404795 C2 RU2404795 C2 RU 2404795C2
Authority
RU
Russia
Prior art keywords
des
mutein
amino acid
sequence
weeks
Prior art date
Application number
RU2007132125/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2007132125A (ru
Inventor
Лоренс ЭЛИАС (US)
Лоренс Элиас
Гэри ВАЙТРЕЛЛ (US)
Гэри ВАЙТРЕЛЛ
Original Assignee
Новартис Вэксинс Энд Диагностикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Вэксинс Энд Диагностикс Инк. filed Critical Новартис Вэксинс Энд Диагностикс Инк.
Publication of RU2007132125A publication Critical patent/RU2007132125A/ru
Application granted granted Critical
Publication of RU2404795C2 publication Critical patent/RU2404795C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2007132125/14A 2005-01-27 2006-01-27 Способы лечения почечно-клеточной карциномы RU2404795C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64749605P 2005-01-27 2005-01-27
US60/647,496 2005-01-27

Publications (2)

Publication Number Publication Date
RU2007132125A RU2007132125A (ru) 2009-03-10
RU2404795C2 true RU2404795C2 (ru) 2010-11-27

Family

ID=36741121

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007132125/14A RU2404795C2 (ru) 2005-01-27 2006-01-27 Способы лечения почечно-клеточной карциномы

Country Status (13)

Country Link
US (2) US20070014765A1 (cg-RX-API-DMAC10.html)
EP (1) EP1846020B1 (cg-RX-API-DMAC10.html)
JP (2) JP2008528621A (cg-RX-API-DMAC10.html)
KR (1) KR20070102576A (cg-RX-API-DMAC10.html)
CN (1) CN101132809A (cg-RX-API-DMAC10.html)
AU (1) AU2006207987B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0606774A2 (cg-RX-API-DMAC10.html)
CA (1) CA2595959A1 (cg-RX-API-DMAC10.html)
ES (1) ES2432141T3 (cg-RX-API-DMAC10.html)
IL (1) IL184865A (cg-RX-API-DMAC10.html)
MX (1) MX2007009012A (cg-RX-API-DMAC10.html)
RU (1) RU2404795C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006081510A2 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370399A4 (en) * 2008-12-11 2013-05-22 Agency Science Tech & Res GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP3443979B2 (en) * 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
US9669071B2 (en) * 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
IL301612A (en) * 2020-10-09 2023-05-01 Synthorx Inc Immuno oncology therapies with il-2 conjugates
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174409C2 (ru) * 1995-11-30 2001-10-10 Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем Способы и композиции для диагностики и лечения рака
WO2004002526A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174409C2 (ru) * 1995-11-30 2001-10-10 Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем Способы и композиции для диагностики и лечения рака
WO2004002526A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMATO R.J., SCHELL J. et al: Phase II study of thalidomide+interleukm-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). Proc ASCO 22:387, (abstr #1556), 2003. VERRA N. et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma., Br J Cancer. 2003 May 6; 88(9): 1346-1351. *
SLEIJFER D.T. et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced., J Clin OncoL, 1992; 10: 1119-1123. *

Also Published As

Publication number Publication date
BRPI0606774A2 (pt) 2009-07-14
IL184865A0 (en) 2007-12-03
IL184865A (en) 2011-04-28
EP1846020B1 (en) 2013-08-21
AU2006207987B2 (en) 2011-09-15
AU2006207987A1 (en) 2006-08-03
JP2012046552A (ja) 2012-03-08
MX2007009012A (es) 2007-09-14
CA2595959A1 (en) 2006-08-03
US20100316595A1 (en) 2010-12-16
RU2007132125A (ru) 2009-03-10
JP2008528621A (ja) 2008-07-31
KR20070102576A (ko) 2007-10-18
US8012465B2 (en) 2011-09-06
WO2006081510A3 (en) 2007-01-18
US20070014765A1 (en) 2007-01-18
CN101132809A (zh) 2008-02-27
ES2432141T3 (es) 2013-11-29
WO2006081510A2 (en) 2006-08-03
EP1846020A2 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
US8012465B2 (en) Methods for treating renal cell carcinoma
JP6718494B2 (ja) 癌を処置するためのペグ化il−10の使用
ES2276698T3 (es) Composiciones farceuticas que contienen un polipeptido liquido estabilizado.
ES2906615T3 (es) Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
AU2010204552B2 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
CN116251173A (zh) 重组人血管内皮抑制素的用途
AU2014208224A1 (en) New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein
KR20140130705A (ko) 체강액 저류 억제제
HK1172248A (en) Use of pegylated il-10 to treat cancer
HK1127553B (en) Use of pegylated il-10 to treat cancer
HK1201182B (en) Pegylated il-10 for use in treating lymphoma

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210128